StockData

Ovid Therapeutics vs Xenon Pharmaceuticals

OVID and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OVID and XENE compare

Xenon Pharmaceuticals is the larger company, worth 8.7 times as much as Ovid Therapeutics ($3.8B against $434M).

Ovid Therapeutics grew revenue faster over the last twelve months (−76.2% versus −100% for Xenon Pharmaceuticals).

Ovid Therapeutics scores higher on the StockData Score (10 against 7 for Xenon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOVIDXENE
Size and price
Market cap$434M$3.8B
Share price$2.22$38.78
Change, 1 year70.1%−4.9%
Change, 5 years−31.9%41.3%
Beta (5Y)1.340.26
Employees23370
StockData Score
Total score10 (better)7
Valuation score1 (better)0
Growth score1 (better)0
Performance score2 (better)1
Health score66
Dividend score00
Valuation
P/S274×–
P/B2.1× (better)3.0×
FCF yield–−9.0%
Growth
Revenue growth (TTM)−76.2% (better)−100%
Revenue growth, 5Y average−10.5% (better)−25.3%
Profitability
Operating margin−3687%–
Net margin−2179%–
Return on equity−26.0% (better)−43.6%
Return on invested capital−160%−152% (better)
Financial health
Debt / equity0.000.00
Current ratio12.3921.02 (better)
Altman Z-score9.4140.35 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions75.3%104%
Held by insiders13.6%0.17%
Insider net buying, 12 months−$29.3K (better)−$20.3M
Superinvestors holding–1
Short interest, % of float10.8%7.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.